[go: up one dir, main page]

DK2207775T3 - 4-Benzylamino-1-carboxyacylpiperidinderivater som CETP-inhibitorer, som er anvendelige til behandling af sygdomme som hyperlipidæmi eller arteriosclerose - Google Patents

4-Benzylamino-1-carboxyacylpiperidinderivater som CETP-inhibitorer, som er anvendelige til behandling af sygdomme som hyperlipidæmi eller arteriosclerose

Info

Publication number
DK2207775T3
DK2207775T3 DK08848438.1T DK08848438T DK2207775T3 DK 2207775 T3 DK2207775 T3 DK 2207775T3 DK 08848438 T DK08848438 T DK 08848438T DK 2207775 T3 DK2207775 T3 DK 2207775T3
Authority
DK
Denmark
Prior art keywords
carboxyacylpiperidine
benzylamino
hyperlipidemia
arteriosclerosis
diseases
Prior art date
Application number
DK08848438.1T
Other languages
English (en)
Inventor
Muneto Mogi
Ken Yamada
Kayo Yasoshima
Toshio Kawanami
Ichiro Umemura
Yuki Iwaki
Hongbo Qin
Hidetomo Imase
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40343337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2207775(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK2207775T3 publication Critical patent/DK2207775T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK08848438.1T 2007-11-05 2008-11-03 4-Benzylamino-1-carboxyacylpiperidinderivater som CETP-inhibitorer, som er anvendelige til behandling af sygdomme som hyperlipidæmi eller arteriosclerose DK2207775T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98545607P 2007-11-05 2007-11-05
PCT/EP2008/064859 WO2009059943A1 (en) 2007-11-05 2008-11-03 4-benzylamino-1-carboxyacyl-piperidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis

Publications (1)

Publication Number Publication Date
DK2207775T3 true DK2207775T3 (da) 2012-06-18

Family

ID=40343337

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08848438.1T DK2207775T3 (da) 2007-11-05 2008-11-03 4-Benzylamino-1-carboxyacylpiperidinderivater som CETP-inhibitorer, som er anvendelige til behandling af sygdomme som hyperlipidæmi eller arteriosclerose

Country Status (25)

Country Link
US (3) US8193349B2 (da)
EP (2) EP2207775B1 (da)
JP (1) JP5555635B2 (da)
KR (1) KR101564793B1 (da)
CN (1) CN101910150B (da)
AR (1) AR069165A1 (da)
AT (1) ATE550333T1 (da)
AU (1) AU2008324243B2 (da)
BR (1) BRPI0819223A2 (da)
CA (1) CA2704633C (da)
CL (1) CL2008003284A1 (da)
CY (1) CY1112706T1 (da)
DK (1) DK2207775T3 (da)
EA (1) EA022912B1 (da)
ES (2) ES2434417T3 (da)
HK (1) HK1168096A1 (da)
HR (1) HRP20120476T1 (da)
JO (1) JO2732B1 (da)
MX (1) MX2010004929A (da)
PE (1) PE20090982A1 (da)
PL (2) PL2207775T3 (da)
PT (2) PT2207775E (da)
SI (1) SI2207775T1 (da)
TW (1) TWI426910B (da)
WO (1) WO2009059943A1 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2229356E (pt) 2007-12-03 2012-01-20 Novartis Ag Derivados de 4-benzilamino-pirrolidina 1,2-dissubstituídos como inibidores de cetp úteis para o tratamento de doenças tais como hiperlipidemia ou arteriosclerose
TWI666209B (zh) 2009-06-17 2019-07-21 美商維泰克斯製藥公司 流感病毒複製之抑制劑
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
MX2013006251A (es) 2010-12-03 2013-10-01 Epizyme Inc Compuestos de purina y 7 - deazapurina substituidos como moduladores de enzimas epigeneticas.
ES2648788T3 (es) 2011-01-26 2018-01-08 Inserm - Institut National De La Santé Et De La Recherche Médicale Método para evaluar el riesgo de un sujeto de tener una enfermedad cardiovascular
KR20140058547A (ko) * 2011-07-05 2014-05-14 버텍스 파마슈티칼스 인코포레이티드 아자인돌을 제조하기 위한 방법 및 중간체
CA2841117A1 (en) * 2011-07-08 2013-01-17 Novartis Ag 1,2-disubstituted-4-benzylamino-piperidinyl derivatives as cetp inhibitors useful for the treatment of atherosclerosis in high triglyceride subjects
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
ES2663946T3 (es) 2011-11-14 2018-04-17 Regeneron Pharmaceuticals, Inc. Composiciones y métodos para aumentar la masa y la fuerza muscular antagonizando específicamente GDF8 y/o Activina A
NZ702154A (en) * 2012-05-25 2016-12-23 Nutech Ventures Amphiphilic cyclobutenes and cyclobutanes
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
CN105612172A (zh) 2013-07-25 2016-05-25 诺华股份有限公司 用于治疗心力衰竭的环状多肽
CN105705167A (zh) 2013-07-25 2016-06-22 诺华股份有限公司 合成的apelin多肽的生物缀合物
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素ａ之抗體及其用途
US9296727B2 (en) 2013-10-07 2016-03-29 Vertex Pharmaceuticals Incorporated Methods of regioselective synthesis of 2,4-disubstituted pyrimidines
JP6618901B2 (ja) 2013-11-13 2019-12-11 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤を調製する方法
CN104788482B (zh) * 2015-01-23 2016-09-14 沧州普瑞东方科技有限公司 一种制备2-氨基嘧啶-5-硼酸频那醇酯的方法
PE20171328A1 (es) 2015-01-23 2017-09-12 Novartis Ag Conjugados de acidos grasos y apelina sintetica con mayor vida media
AU2016249015B2 (en) 2015-04-15 2022-03-24 Regeneron Pharmaceuticals, Inc. Methods of increasing strength and functionality with GDF8 inhibitors
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
JP6704416B2 (ja) 2015-05-13 2020-06-03 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤を調製する方法
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
MA52417A (fr) 2018-03-01 2021-01-06 Regeneron Pharma Procédés de modification de composition corporelle

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US4617307A (en) 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
US4889861A (en) 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
US5508272A (en) 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
TW313568B (da) 1994-12-20 1997-08-21 Hoffmann La Roche
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6140342A (en) 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
EP1589000A3 (en) 1998-09-25 2006-03-15 Monsanto Company (R)-Chiral halogenated 1-substitutedamino-(N+1)-alkanols useful for inhibiting cholesteryl ester transfer protein activity
AUPP818099A0 (en) 1999-01-14 1999-02-11 Fujisawa Pharmaceutical Co., Ltd. New n-containing heterocyclic compounds
US6476057B1 (en) 1999-09-23 2002-11-05 G.D. Searle & Co. Use of substituted N, N-disubstituted cycloalkyl aminoalcohol compounds for inhibiting cholesteryl ester transfer protein activity
EP1294752A2 (en) 2000-06-16 2003-03-26 Curis, Inc. Angiogenesis-modulating compositions and uses
GB0021885D0 (en) 2000-09-06 2000-10-18 Fujisawa Pharmaceutical Co New use
US7109204B2 (en) 2001-08-01 2006-09-19 Merck & Co., Inc. Tyrosine kinase inhibitors
CN104383554B (zh) 2002-09-06 2018-06-08 天蓝制药公司 用于传递治疗剂的以环糊精为基础的聚合物
TW200408393A (en) 2002-10-03 2004-06-01 Ono Pharmaceutical Co Antagonist of lysophosphatidine acid receptor
US20070010529A1 (en) 2003-05-19 2007-01-11 Kanji Takahashi Nitrogenous heterocyclic compounds and medical use thereof
BRPI0414671A (pt) * 2003-09-30 2006-11-21 Pfizer Prod Inc inibidores da cetp e metabolitos dos mesmos
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
DK1732933T3 (da) 2004-03-26 2008-10-27 Lilly Co Eli Forobindelser til behandling af dyslipidæmi
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
TWI345568B (en) 2004-04-02 2011-07-21 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same
US20060063803A1 (en) * 2004-09-23 2006-03-23 Pfizer Inc 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
US7700774B2 (en) 2004-12-20 2010-04-20 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds and their pharmaceutical compositions
US20060270675A1 (en) 2005-03-10 2006-11-30 Groneberg Robert D Inhibitors of cholesterol ester transfer protein
WO2006098394A1 (ja) 2005-03-14 2006-09-21 Japan Tobacco Inc. 脂質吸収抑制方法および脂質吸収抑制剤
MY150958A (en) 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
JP4258499B2 (ja) * 2005-07-25 2009-04-30 ヤマハ株式会社 吹奏電子楽器の音源制御装置とプログラム
CA2637057A1 (en) 2006-01-13 2007-07-26 Schering Corporation Diaryl piperidines as cb1 modulators
PE20071025A1 (es) 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp Compuesto amina trisustituido
WO2007107843A1 (en) 2006-03-22 2007-09-27 Pfizer Products Inc. Methods of treatment with cetp inhibitors
UY30244A1 (es) 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
KR101149274B1 (ko) 2006-07-20 2012-05-29 노파르티스 아게 Ｃετρ 억제제로서의 아미노-피페리딘 유도체
JP4834699B2 (ja) 2007-07-30 2011-12-14 田辺三菱製薬株式会社 医薬組成物
JP4846769B2 (ja) 2007-07-30 2011-12-28 田辺三菱製薬株式会社 医薬組成物
PT2229356E (pt) 2007-12-03 2012-01-20 Novartis Ag Derivados de 4-benzilamino-pirrolidina 1,2-dissubstituídos como inibidores de cetp úteis para o tratamento de doenças tais como hiperlipidemia ou arteriosclerose
CN101883764B (zh) 2007-12-07 2013-11-13 诺华股份有限公司 吡唑衍生物及其作为细胞周期蛋白依赖性激酶抑制剂的用途

Also Published As

Publication number Publication date
AU2008324243A1 (en) 2009-05-14
KR101564793B1 (ko) 2015-10-30
US8440682B2 (en) 2013-05-14
EP2463282A1 (en) 2012-06-13
KR20100094986A (ko) 2010-08-27
US8193349B2 (en) 2012-06-05
CL2008003284A1 (es) 2009-05-15
CY1112706T1 (el) 2016-02-10
CA2704633C (en) 2015-10-20
CN101910150B (zh) 2013-09-18
TWI426910B (zh) 2014-02-21
AU2008324243B2 (en) 2012-03-08
MX2010004929A (es) 2010-05-27
HRP20120476T1 (hr) 2012-06-30
US20090118287A1 (en) 2009-05-07
CN101910150A (zh) 2010-12-08
JP5555635B2 (ja) 2014-07-23
WO2009059943A1 (en) 2009-05-14
PT2207775E (pt) 2012-05-11
EA201000750A1 (ru) 2010-12-30
ES2381518T3 (es) 2012-05-29
EA022912B1 (ru) 2016-03-31
ATE550333T1 (de) 2012-04-15
BRPI0819223A2 (pt) 2020-08-18
US20120208816A1 (en) 2012-08-16
US8420641B2 (en) 2013-04-16
HK1168096A1 (en) 2012-12-21
TW200924779A (en) 2009-06-16
US20120264773A1 (en) 2012-10-18
SI2207775T1 (sl) 2012-05-31
EP2463282B1 (en) 2013-08-07
AR069165A1 (es) 2010-01-06
PL2207775T3 (pl) 2012-08-31
CA2704633A1 (en) 2009-05-14
EP2207775B1 (en) 2012-03-21
EP2207775A1 (en) 2010-07-21
PE20090982A1 (es) 2009-08-13
ES2434417T3 (es) 2013-12-16
JP2011503026A (ja) 2011-01-27
PL2463282T3 (pl) 2014-01-31
JO2732B1 (en) 2013-09-15
PT2463282E (pt) 2013-11-11

Similar Documents

Publication Publication Date Title
DK2207775T3 (da) 4-Benzylamino-1-carboxyacylpiperidinderivater som CETP-inhibitorer, som er anvendelige til behandling af sygdomme som hyperlipidæmi eller arteriosclerose
DK3456707T3 (da) 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme
DK2300443T3 (da) Triazolderivater, der er anvendelige til behandling af sygdomme
DK2040713T3 (da) Galdesyrederivater som fxr-ligander til forebyggelsen eller behandlingen af fxr-medierede sygdomme eller tilstande
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
SMP200900085B (it) 3-imidazolil-indoli per il trattamento di malattieproliferative.
DK3434687T3 (da) Hidtil ukendte oxyntomodulinderivater og farmaceutisk præparat til behandling af fedme omfattende samme
DK2220076T3 (da) Inhibitorer af replikationen af humant immundefektvirus
DK3517534T3 (da) Forbindelser, der er anvendelige til behandling af cancer
ES2352576T8 (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana.
DK2086944T3 (da) Fremgangsmåde til fremstilling af difluormethylpyrazolylcarboxylater
DK2139892T3 (da) Substituerede pyrimidodiazepiner nyttige som PLK1-inhibitorer
DK3289876T3 (da) Forbindelser til behandling af cancer
DK2315756T3 (da) 1,2,5-oxadiazoler som inhibitorer af indolamin-2,3-dioxygenase
DK2349310T3 (da) Polypeptid til behandling eller forebyggelse af adhæsioner
DK2114886T3 (da) Fremgangsmåde til fremstilling af visse substituerede sulfiliminer
DK2478907T3 (da) Sammensætninger til behandling af kræft
DK2154971T3 (da) Synergistisk farmaceutisk kombination til behandling af cancer
DK2220070T3 (da) 2-benzylpyridazinonderivater som Met-kinaseinhibitorer
DK2216021T3 (da) Farmaceutisk sammensætning til behandling af overaktiv blære
DK3689346T3 (da) 3,6-disubstitueret xanthyliumsalte til behandling af tauopati
DK2117565T3 (da) Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme
DK2321359T3 (da) Fremgangsmåde til behandling af naturlige gummiprodukter
DK2296651T3 (da) 5-hydroxymethyl-oxazolidin-2-on-derivater til behandling af bakterielle intestinale sygdomme
DK2285416T3 (da) Konjugat til behandlingen af mesotheliom